CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 29 enrolled
Drug / intervention
Dipyridamole +1 moredrug
Likely dose
Dipyridamole 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00349973
NCT00349973N/ACompleted
CompareCT.gov

Clinical Trial of Dipyridamole in Schizophrenia

University of Maryland, Baltimore·interventional·Posted Jul 10, 2006·Updated Nov 4, 2019

In Brief

A clinical study evaluating Dipyridamole and Olanzapine for Schizophrenia and 2 related conditions. Completed, enrolled 29 participants across 1 site.

Detailed Summary

This is a 6-week, randomized, double blind, parallel groups designed, olanzapine-controlled trial of oral dipyridamole in symptomatic patients with a (DSM IV) diagnosis of schizophrenia, schizoaffective or schizophreniform disorder. This pilot study aims to provide preliminary estimates of whether the effect sizes of dipyridamole on positive symptoms, negative symptoms, and cognitive deficits differ between schizophrenia patients treated with dipyridamole, and schizophrenia patients treated with olanzapine. A total of 30 subjects will be recruited locally.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 10, 2006
Enrollment StartMay 1, 2001
Primary CompletionSep 1, 2008
Study CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 20.0 years ago

Interventions

Dipyridamoledrug

Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm

Olanzapineother

Week 1- 5 mg BID Week 2- 5 mg am and 10 mg pm Weeks 3-6 10 mg am and 10 mg pm